Literature DB >> 2995432

Circulating activated B cells in primary biliary cirrhosis.

S P James, E A Jones, J H Hoofnagle, W Strober.   

Abstract

Since patients with primary biliary cirrhosis (PBC) have evidence of abnormal function of the humoral immune system, we determined if B cells from patients with this disease show evidence of activation and can be stimulated by polyclonal activators. Using a reverse hemolytic plaque assay, it was found that patients with PBC had a significant increase in the number of circulating immunoglobulin-secreting cells, compared to normal controls and patients with chronic type B hepatitis virus (HBV) infection. However, the total number of activated cells was less than 1% of the total circulating B-cell population. Furthermore, we were unable to detect an increase in the expression of transferrin receptors, a membrane receptor associated with B-cell activation, in the majority of B cells in patients with PBC. In other studies, immunoglobulin production by lymphocytes from patients with PBC, when stimulated with the polyclonal activators pokeweed mitogen and Epstein-Barr virus (EBV), was reduced. This hyporesponsiveness was not due to a decrease in the number of B cells, as determined by staining with the monoclonal antibody anti-Leu 12. Furthermore, the decreased response to B cells to polyclonal activation in PBC patients was not due increased suppressor T-cell function, since EBV-simulated cultures of lymphocytes from patients with PBC demonstrated diminished suppression of immunoglobulin-secreting cells after 14 days of culture compared to controls. These findings suggest that the humoral abnormalities in PBC are due to the activation of a small subpopulation of B cells rather than to generalized B-cell hyperactivity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995432     DOI: 10.1007/bf00929460

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  27 in total

1.  High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis.

Authors:  R M Galbraith; M Smith; R M Mackenzie; D E Tee; D Doniach; R Williams
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

2.  The primary immune response to haemocyanin in patients with primary biliary cirrhosis.

Authors:  R A Fox; F J Dudley; S Sherlock
Journal:  Clin Exp Immunol       Date:  1973-08       Impact factor: 4.330

3.  T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individuals.

Authors:  G Tosato; I T Magrath; R M Blaese
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

4.  Differential expression of cell activation markers after stimulation of resting human B lymphocytes.

Authors:  J H Kehrl; A Muraguchi; A S Fauci
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

5.  Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus.

Authors:  R M Blaese; J Grayson; A D Steinberg
Journal:  Am J Med       Date:  1980-09       Impact factor: 4.965

6.  The role of the transferrin receptor in human B lymphocyte activation.

Authors:  L M Neckers; G Yenokida; S P James
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

7.  Studies of congenic MRL-Ipr/Ipr.xid mice.

Authors:  E B Steinberg; T J Santoro; T M Chused; P A Smathers; A D Steinberg
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

8.  Genetic abnormalities of immunoregulation in primary biliary cirrhosis.

Authors:  K B Miller; R A Sepersky; K M Brown; M J Goldberg; M M Kaplan
Journal:  Am J Med       Date:  1983-07       Impact factor: 4.965

9.  NIH conference: Primary biliary cirrhosis: a model autoimmune disease.

Authors:  S P James; J H Hoofnagle; W Strober; E A Jones
Journal:  Ann Intern Med       Date:  1983-10       Impact factor: 25.391

10.  Frequencies of the separate human B cell subsets activatable to Ig secretion by Epstein-Barr virus and pokeweed mitogen.

Authors:  O Martínez-Maza; S Britton
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more
  7 in total

1.  Lymphocytes from patients with primary biliary cirrhosis spontaneously secrete high levels of IgG3 in culture.

Authors:  P Bird; J E Calvert; H Mitchison; N R Ling; M Bassendine; O F James
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

Review 2.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

3.  Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis.

Authors:  S Kakumu; T Shinagawa; T Ishikawa; K Yoshioka; T Wakita; N Ida
Journal:  Gastroenterol Jpn       Date:  1993-02

4.  Defective proliferation and regulatory function of CD4+ T cells bearing Leu-8 homing receptor in primary biliary cirrhosis. Phorbol myristate acetate enhances T-cell function.

Authors:  R Moreno-Otero; Y Murakawa; M E Kanof; M P Civeira; E A Jones; S P James
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

5.  CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.

Authors:  Michael P Pender
Journal:  Autoimmune Dis       Date:  2012-01-24

Review 6.  Popular and unpopular infectious agents linked to primary biliary cirrhosis.

Authors:  Andreas L Koutsoumpas; Stephen Kriese; Eirini I Rigopoulou
Journal:  Auto Immun Highlights       Date:  2012-10-23

Review 7.  Linking Human Betaretrovirus with Autoimmunity and Liver Disease in Patients with Primary Biliary Cholangitis.

Authors:  Hussain Syed; Tara Penner; Andrew L Mason
Journal:  Viruses       Date:  2022-08-31       Impact factor: 5.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.